Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns.
作者信息
Kumar Aman, Agarwal Divya, Kumar Atul
机构信息
Dr. Rajendra Prasad Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi, India.
出版信息
Indian J Ophthalmol. 2021 Feb;69(2):357-358. doi: 10.4103/ijo.IJO_39_21.
Abstract
摘要
相似文献
1
Commentary: Use of biosimilars for retinal diseases in India: Challenges and concerns.评论：印度视网膜疾病生物类似药的使用：挑战与担忧
Indian J Ophthalmol. 2021 Feb;69(2):357-358. doi: 10.4103/ijo.IJO_39_21.
2
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
3
Biosimilars for Retinal Diseases: An Update.视网膜疾病的生物类似药：最新进展
Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9.
4
Biosimilars for retinal diseases: United States-Europe awareness survey (Bio-USER - survey).视网膜疾病生物类似药：美国-欧洲认知度调查（Bio-USER调查）
Expert Opin Biol Ther. 2023 Jul-Dec;23(8):851-859. doi: 10.1080/14712598.2023.2176218. Epub 2023 Feb 19.
5
Coming of Age: Biosimilars.
Ophthalmic Surg Lasers Imaging Retina. 2018 Mar 1;49(3):162-165. doi: 10.3928/23258160-20180221-02.
6
Biosimilars for the Treatment of Retinal Diseases.用于治疗视网膜疾病的生物类似药。
Ophthalmic Surg Lasers Imaging Retina. 2021 May;52(5):242-246. doi: 10.3928/23258160-20210429-01. Epub 2021 May 1.
7
Commentary: Anti-vascular endothelial growth factor therapies in vitreo-retina practice: Biosimilars versus biologics.评论：玻璃体内视网膜治疗中的抗血管内皮生长因子疗法：生物类似药与生物制品的对比
Indian J Ophthalmol. 2021 Feb;69(2):358-359. doi: 10.4103/ijo.IJO_40_21.
8
Biosimilars for Retinal Diseases: Understanding the Phase 3 Clinical Trial Design.
Ophthalmology. 2022 Jan;129(1):65-66. doi: 10.1016/j.ophtha.2021.09.008. Epub 2021 Sep 15.
9
Biosimilars for Retinal Diseases: A Review of the Literature.
Int Ophthalmol Clin. 2024 Jan 1;64(1):129-139. doi: 10.1097/IIO.0000000000000509. Epub 2023 Dec 26.
10
Biosimilars in India.印度的生物类似药。
J Proteomics. 2015 Sep 8;127(Pt A):71-2. doi: 10.1016/j.jprot.2015.08.005. Epub 2015 Aug 13.
引用本文的文献
1
Suppressing Inflammation for the Treatment of Diabetic Retinopathy and Age-Related Macular Degeneration: Dazdotuftide as a Potential New Multitarget Therapeutic Candidate.抑制炎症用于治疗糖尿病性视网膜病变和年龄相关性黄斑变性：达佐肽作为一种潜在的新型多靶点治疗候选药物
Biomedicines. 2023 May 27;11(6):1562. doi: 10.3390/biomedicines11061562.
2
Commentary: Biosimilars in the treatment of retinopathy of prematurity.评论：生物类似药在早产儿视网膜病变治疗中的应用
Indian J Ophthalmol. 2023 Feb;71(2):416-417. doi: 10.4103/ijo.IJO_2254_22.
3
Diabetic Macular Edema: Current Understanding, Molecular Mechanisms and Therapeutic Implications.糖尿病性黄斑水肿：当前认识、分子机制及治疗意义。
Cells. 2022 Oct 25;11(21):3362. doi: 10.3390/cells11213362.
4
Commentary: An insight into the preferred practice of vitreoretinal specialists of India: Medical retina.评论：深入了解印度玻璃体视网膜专家的首选实践：医学视网膜。
Indian J Ophthalmol. 2021 Jun;69(6):1440-1441. doi: 10.4103/ijo.IJO_1062_21.
本文引用的文献
1
Changing trends in the use of anti-vascular endothelial growth factor (anti-VEGF) biosimilars: Insights from the Vitreoretinal Society of India Biosimilars of Anti-VEGF Survey.抗血管内皮生长因子（anti-VEGF）生物类似药使用变化趋势：来自印度玻璃体视网膜学会抗 VEGF 生物类似药调查的见解。
Indian J Ophthalmol. 2021 Feb;69(2):352-356. doi: 10.4103/ijo.IJO_2703_20.
2
Biosimilars for Retinal Diseases: An Update.视网膜疾病的生物类似药：最新进展
Am J Ophthalmol. 2021 Apr;224:36-42. doi: 10.1016/j.ajo.2020.11.017. Epub 2020 Dec 9.
3
A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein Occlusion.一项关于Razumab™（全球首款雷珠单抗生物类似药）用于视网膜静脉阻塞的多中心回顾性研究（RE-ENACT 2）。
Ophthalmol Ther. 2020 Sep;9(3):625-639. doi: 10.1007/s40123-020-00277-3. Epub 2020 Jul 2.
4
Managing intravitreal injections in adults in COVID-19 and post-COVID-19 era- Initial experiences.在新冠疫情及后新冠疫情时代管理成人玻璃体内注射——初步经验
Indian J Ophthalmol. 2020 Jun;68(6):1216-1218. doi: 10.4103/ijo.IJO_1391_20.
5
Commentary: Restructuring residency training in ophthalmology during COVID-19 era: Challenges and opportunities.评论：新冠疫情时代眼科住院医师培训的重组：挑战与机遇
Indian J Ophthalmol. 2020 Jun;68(6):1005-1006. doi: 10.4103/ijo.IJO_1462_20.
6
Resident-to-resident bedside teaching: An innovative concept.住院医师对住院医师的床边教学：一种创新理念。
Indian J Ophthalmol. 2019 Nov;67(11):1901-1902. doi: 10.4103/ijo.IJO_909_19.
7
Commentary: Improving training in retina in Indian residency programmes.评论：改进印度住院医师培训项目中的视网膜培训
Indian J Ophthalmol. 2019 Nov;67(11):1819-1820. doi: 10.4103/ijo.IJO_1441_19.
8
Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT Study.雷珠单抗生物类似药Razumab®（全球首个雷珠单抗生物类似药）在视网膜静脉阻塞中的真实临床疗效：汇总回顾性RE-ENACT研究的亚组分析
Ophthalmologica. 2019;241(1):24-31. doi: 10.1159/000488602. Epub 2018 Jun 26.
9
Rationale, Opportunities, and Reality of Biosimilar Medications.生物类似药的基本原理、机遇与现实
N Engl J Med. 2018 May 24;378(21):2036-2044. doi: 10.1056/NEJMhle1800125.
10
Identification of multiple serine to asparagine sequence variation sites in an intended copy product of LUCENTIS® by mass spectrometry.通过质谱法鉴定雷珠单抗生物类似药预期复制产物中的多个丝氨酸到天冬酰胺序列变异位点。
MAbs. 2017 Nov/Dec;9(8):1337-1348. doi: 10.1080/19420862.2017.1366395. Epub 2017 Aug 28.
Zotero 插件